Articles On Neuren Pharmaceuticals (ASX:NEU)

A drug developed by Neuren Pharmaceuticals (ASX: NEU) to treat debilitating childhood neurodevelopmental disorders has been granted an orphan drug designation by the US Food and Drug Administration. Drug candidate NNZ-2591 has previously de...

The Federal agency of the United States Department of Health and Human Services, US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren Pharmaceuticals’ (ASX: NEU) NNZ-2591. Neuren’s NNZ-2591 drug is used in th...

Agri-tech business Roots Sustainable Agricultural Technologies (ASX:ROO) says its crop-cooling technology continues to gain traction with commercial cannabis producers. The Israeli-based company released results from the operation of its Ro...

US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren Pharmaceuticals’ (ASX: NEU) NNZ-2591 for the treatment of Angelman syndrome. Orphan Drug designation is a special status that the FDA may grant to a drug to...

The S&P/ASX 200 index looks set to finish the week on a high on Friday. In afternoon trade the benchmark index is up 0.65% to 6,761.1 points. Four shares that have failed to follow the market higher today are listed below. Here’s why t...

Even though the stock markets are sensitive to the global macro-economic parameters, in the present scenario, the investors need to maintain their focus towards the US corporate earnings. The companies, generally, provide information on how...

Healthcare Healthcare sector comprises of the companies that offer medical services, producing medical equipment or medicines. These companies also give medical insurance to the patients. In Australia, the funding of healthcare is taken ca...

In the never-ending battle against bacteria, Next Science (ASX:NSX) has adopted a ‘take no prisoners’ approach in eradicating the bodily bolt holes in which these pathogens congregate and quietly multiply. With a suite of four approved prod...